Status:
COMPLETED
A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban
Lead Sponsor:
Portola Pharmaceuticals
Conditions:
Bleeding
Eligibility:
All Genders
50-75 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the ability of Andexanet Alfa to reverse the anticoagulation effect of Rivaroxaban.
Eligibility Criteria
Inclusion
- Reasonably healthy men and women aged 50 to 75
Exclusion
- History of abnormal bleeding, active bleeding or risk factors for bleeding
- History of thrombosis or risk factors for thrombosis
- History of adult asthma or use of inhaled medications
Key Trial Info
Start Date :
May 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2015
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT02220725
Start Date
May 1 2014
End Date
August 1 2015
Last Update
February 10 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
West Coast Clinical Trials
Cypress, California, United States, 90630